Endometrial changes with chronic tamoxifen use

Current Opinion in Obstetrics and Gynecology

Volumn 9, Issue 3, 1997, Pages 160-164

  Loret De Mola, J Ricardo ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TAMOXIFEN;

BREAST CARCINOMA; CANCER GRADING; CANCER RISK; ENDOMETRIUM; ENDOMETRIUM CANCER; ENDOMETRIUM HYPERPLASIA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; REVIEW; VAGINA BLEEDING;

EID: 0030789210     PISSN: 1040872X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001703-199706000-00004     Document Type: Review

References (43)

1. Early Breast Cancer Trialists' Collaborative Group: Effect of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women. N Engl J Med 1988, 319:1681-1692.
2. Jordan VC: Estrogens and antiestrogens. In Cancer Medicine, edn 3. Section XVII: Principles of Endocrine Therapy. Vol. 1. Edited by Holland JF. Philadelphia: Lea and Febiger; 1993:857-868.
3. Tamoxifen and endometrial cancer. American College of Obstetricians and Gynecologists Committee Opinion 1996, 169 (February). This review represents the current position of the American College of Obstetricians and Gynecologists regarding tamoxifen, and the risk for endometrial cancer.
4. Gelber RD, Cole BF, Goldhirsch A, Rose C, Fisher B, Osborne CK, Boccardo F, Gray R, Gordon NH, Bengtsson NO, Sevelda P: Adjuvant chemotherapy plus tamoxifen compared with tamoxifen alone for post-menopausal breast cancer: meta-analysis of quality-adjusted survival. Lancet 1996, 347:1066-1071. This study describes a meta-analysis to find if adding chemotherapy to tamoxifen outweighs its costs in terms of toxic effects for postmenopausal patients, based on data from 3920 patients aged 50 years or older with node-positive breast cancer.
5. Sasco AJ, Chaplain G, Amoros E, Saez S: Endometrial cancer following breast cancer: effect of tamoxifen and castration by radiotherapy. Epidemiology 1996, 7:9-13.
6. Cohen CJ, Rahaman J: Endometrial cancer: management of high risk and recurrence including the Tamoxifen controversy. Cancer 1995, 76:2044-2052.
7. Fisher B, Costantino JP, Redmond CK, Fisher ER, Wickerham DL, Cronin WM: Endometrial cancer in tamoxifen treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Nat Cancer Inst 1994, 86:527-537.
8. Stewart HJ, Forrest AP, Everington D, McDonald CC, Dewar JA, Hawkins RA, Prescott RJ, George WD: Randomized comparison of 5 years of adjuvant tamoxifen with continuous therapy for operable breast cancer. The Scottish Cancer Trials Breast Group. Br J Cancer 1996, 74:297-299.
9. Fornander T, Rutqvist LE, Cedermark B, Glas U, Mattsson A, Silfversward C, Skoog L, Somell A, Theve T, Wilking N: Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers. Lancet 1989, 2:117-120.
10. Anderson M, Storm HH, Mouridsen HT: Carcinogenic effects of adjuvant tamoxifen treatment and radiotherapy for early breast cancer. Acta Oncol 1992, 31:259-263.
11. Sunderland MC, Osborne CK: Tamoxifen in pre-menopausal patients with metastatic breast cancer: a review. J Clin Oncol 1991, 9:1283-1297.
12. Fisher B: Commentary on endometrial cancer deaths in tamoxifen-treated breast cancer patients. J Clin Oncol 1996, 14:1027-1039.
13. Marshal E: Tamoxifen's trials and tribulations [letter]. Science 1995, 270:910
14. Cano A, Matellin P, Legua V, Tortajada M, Bonilla-Musoles F: Tamoxifen and the uterus and endometrial [editorial]. Lancet 1989, 1:376.
15. Ford MR, Turner MJ, Wood C, Soutter WP: Endometriosis developing during tamoxifen therapy. Am J Obstet Gynecol 1988, 158:1119.
16. Boudouris O, Ferrand S, Guillet JL, Madelenat P: Paradoxical effects of tamoxifen on the woman's uterus. Apropos of 7 cases of myoma that appeared while under antiestrogen treatment J Gynecol Obstet Biol Reprod (Paris) 1989, 18:372-378.
17. Powles TJ, Hardy JR, Ashley SE, Farrington GM, Cosgrove D, Davey JB, Dowsett M, McKinna JA, Nash AG, Sinnett HD: A pilot trial to evaluate the acute toxicity and feasibility of tamoxifen for prevention of breast cancer. Br J Cancer 1989, 60:126-131.
18. Nephew KP, Polek TC, Khan SA: Tamoxifen-induced proto-oncogene expression persists in uterine endometrial epithelium. Endocrinology 1996, 137:219-224.
19. Kleinman D, Karas M, Danilenko M, Arbell A, Roberts CT, LeRoith D, Levy J, Sharoni Y: Stimulation of endometrial cancer cell growth by tamoxifen is associated with increased insulin-like growth factor-I (IGF-I) induced tyrosine phosphorylation and reduction in IGF binding proteins. Endocrinology 1996, 137:1089-1095.
20. Cohen I, Altaras MM, Shapira J, Tepper R, Rosen DJ, Cordoba M, Zalel Y, Figer A, Yigael D, Beyth Y: Time-dependent effect of tamoxifen therapy on endometrial pathology in asymptomatic post-menopausal breast cancer patients, Int J Gynecol Pathol 1996, 15:152-157. This study presents data regarding a link between length of exposure of tamoxifen and endometrial cancer.
21. Barakat RR, Wong G, Curtin JP, Vlamis V, Hoskins WJ: Tamoxifen use in breast cancer patients who subsequently develop corpus cancer is not associated with a higher incidence of adverse histologic features. Gynecol Oncol 1994, 55:164-168.
22. Sismondi P, Biglia N, Volpi E, Giai M, de Grandis T: Tamoxifen and endometrial cancer. Ann N Y Acad Sci 1994, 734:310-321.
23. Bissett D, Davis JA, George WD: Gynaecological monitoring during tamoxifen therapy [letter]. Lancet 1994, 344:1244.
24. Magriples U, Naftolin F, Schwartz PE, Carcangiu ML: High-grade endometrial carcinoma in tamoxifen-treated breast cancer patients. J Clin Oncol 1993, 11:485-490.
25. Ismail SM: Pathology of endometrium treated with tamoxifen. J Clin Pathol 1994, 47:827-833.
26. Peterson WF, Novak ER: Endometrial polyps. Obstet Gynecol 1956, 8:40-49.
27. McGonigle KF, Lantry SA, Odom-Maryon TL, Chai A, Vasilev SA, Simpson JF: Histopathologic effects of tamoxifen on the uterine epithelium of breast cancer patients: analysis by menopausal status. Cancer Lett 1996, 101:59-66.
28. Sasco AJ, Raffi F, Satge D, Goburdhun J, Fallouh B, Leduc B: Endometrial mullerian carcinosarcoma after cessation of tamoxifen therapy for breast cancer, Int J Obstet Gynecol 1995, 48:307-310.
29. Decensi A, Fontana V, Bruno S, Gustavino C, Gatteschi B, Costa A: Effect of tamoxifen on endometrial proliferation. J Clin Oncol 1996, 14:434-440.
30. McBride JM: Pre-menopausal cystic hyperplasia and endometrial carcinoma. J Obstet Gynecol Br Emp 1959, 66:288-296.
31. Kurman RJ, Kaminski PF, Norris HJ: The behavior of endometrial hyperplasia. A long term study of untreated hyperplasia in 170 patients. Cancer 1985, 56:403-412.
32. Armenia CS: Sequential relationship between endometrial polyps and carcinoma of the endometrium. Obstet Gynecol 1967, 30:524-529.
33. Cuenca RE, Giachino J, Arredondo MA, Hempling R, Edge SB: Endometrial carcinoma associated with breast carcinoma: low incidence with tamoxifen use. Cancer 1996, 77:2058-2063. The authors concluded that the incidence of endometrial cancer in tamoxifen users is low and the value of routine invasive screening is questioned.
34. Rayter Z, Gazet JC, Shepherd J, Trott PA, Fisher C, Svensson WE, Ford HT, A'Hern T: Gynaecological cytology and pelvic ultrasonography in patients with breast cancer taking tamoxifen compared with controls. Eur J Surg Oncol 1994, 20:134-140.
35. Neven P, De Muylder X, Van Belle Y, Vanderick G, De Muylder E: Tamoxifen and the uterus and endometrium. Lancet 1989, 1:375-376.
36. De Muylder X, Neven P, De Somer M, Van Belle Y, Vanderick G, De Muylder E: Endometrial lesions in patients undergoing tamoxifen therapy, Int J Gynecol Obstet 1991, 36:127-130.
37. Kedar RP, Bourne TH, Powles TJ, Collins WP, Ashley SE, Cosgrove DO, Campbell S: Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomized breast cancer prevention trial. Lancet 1994, 343:1318-1321.
38. Reilly DT, Taylor MA: Lack of induction of endometrial hyperplasia with tamoxifen. Lancet 1995, 345:254-255.
39. Ascher SM, Johnson JC, Barnes WA, Bae CJ, Patt RH, Zeman RK: MR imaging appearance of the uterus in post-menopausal women receiving tamoxifen therapy for breast cancer: histopathologic correlation. Radiology 1996, 200:105-110.
40. Ingle J: Tamoxifen and endometrial cancer: new challenges for an old drug. Gynecol Oncol 1994, 55:161-163.
41. Scarselli G, Tantini C, Colafranceschi M, Taddei GL, Bargelli G, Venturini N, Branconi F: Levo-norgestrel-nova T and pre-cancerous lesions of the endometrium. Eur J Gynecol Oncol 1988, 9:284-286.
42. Anderson K, Mattson LA, Rybo G, Stadberg E: Intrauterine release of levonorgestrel: a new way of adding progestogen in hormone replacement therapy. Obstet Gynecol 1992, 79:963-967.
43. Daniel Y, Inbar M, Bar-Am A, Peyser MR, Lessing JB: The effects of tamoxifen treatment on the endometrium. Fertil Steril 1996, 65:1083-1089. A literature review regarding tamoxifen treatment in breast carcinoma. The authors conclude that the risk of breast cancer recurrence overrides the chances of developing endometrial carcinoma. They advise that any vaginal bleeding in women treated with tamoxifen should be investigated carefully and promptly.